Hints and tips:
...Two DBS trials sponsored by medical technology companies were stopped early because they were not delivering clear benefits....
...It’s not just Covax that has disappointed, Love says: the Covid-19 Technology Access Pool (C-TAP), a sharing mechanism for coronavirus-related medical data and research housed at the World Health Organization...
...Medical experts warn that the president is entering a pivotal, unpredictable phase (NYT)....
...One of the most intriguing trends of our times is that of reverse innovation, where ideas pioneered in the developing world are applied in the developed world, too....
...Officials insisted that the main current issues were more to do with the distribution of kit, rather than supply....
...on Scientific, Technical, and Medical (STM) information and to flag the appealing risk/reward on Exhibitions....
...The company will now look to raise c.$200M in new equity to complete the deal....
...CCL’s current Price/BV stands at 0.39x, vs an average P/BV of 1x over the last year and a longer term average of 1.45x. On our TP, the implied P/BV is 0.50x....
...of time and close monitoring of inventories and receivables; iv) the company will not use the partial unemployment scheme in France (comments regarding Italy were less clear); v) the FY19 dividend will...
...Fever - having a good C-19. We have previously highlighted that Fever is having a good C-19....
...However, EBIT missed company compiled consensus by 12% (€6mn) due to a c.25% drop in spares revenues and the GTF warranty work dilution....
...The most tangible outputs from this are cost efficiencies (for example, payroll and marketing savings of c.£44m and c.£16m p.a. respectively, and distribution cost leverage through simple measures to drive...
...applied through the multi-year global financial crisis....
...The T&C's refer only to "Content" and define that the company can “use, copy, reproduce, process, adapt, modify, publish, transmit, display and distribute such Content in any and all media or distribution...
...From what we see,the company’s current approach to fixed-cost allocation is completely appropriate, but the effects are magnified by effectively being a one-product company....
...The ONS estimates the value of land and assets-over-land to be over £5tn compared to a GDP of c£2tn....
..., for example; and c) limiting the power of researchers to undertake genuine research which could be for wider medical or social benefit or even detect and prevent cyber attacks....
...I recognised well-known brands — 3M, C&A, H&M. So much for corporate social responsibility, though the companies may well have been unaware that prison labour was part of their supply chain....
...This is bad news for translational medicine and the development of medical ideas into surgical practice....
...We've applied to the EMA. We've applied to the FDA. It doesn't matter so much geographically where that entity takes place....
...Medical device maker Surgical Innovations said it would report exceptional charges of £1.6m in its 2014 accounts after a review of its balance sheet....
...So I say, well, it’s a, b, c, whenever he forces . . ....
...This requirement should be uniformly applied to the private sector as well as listed public sector companies....
...As publishers, we know the value of access to knowledge and that it can be applied to transforming healthcare....
International Edition